Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure.

about

Effects of tolvaptan on renal function in chronic kidney disease patients with volume overload

P2860

Q58770191-13AB37C5-CE53-4E15-96BD-484CD5A3CDB1

P2860

Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure.

Item

http://www.wikidata.org/entity/Q38965320

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure.

@en

type

Item

label

Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure.

@en

prefLabel

Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure.

@en

P1476

Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure

@en

P2093

Akira Fujiwara

http://www.w3.org/2001/XMLSchema#string

Gen Yasuda

http://www.w3.org/2001/XMLSchema#string

Keisuke Yatsu

http://www.w3.org/2001/XMLSchema#string

Koichiro Sumida

http://www.w3.org/2001/XMLSchema#string

Kouichi Tamura

http://www.w3.org/2001/XMLSchema#string

Mari Katsumata

http://www.w3.org/2001/XMLSchema#string

Mayumi Kobayashi

http://www.w3.org/2001/XMLSchema#string

Megumi Fujita

http://www.w3.org/2001/XMLSchema#string

Minako Kagimoto

http://www.w3.org/2001/XMLSchema#string

Sanae Saka

http://www.w3.org/2001/XMLSchema#string

P2860

Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial

Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial

Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease

Hyponatremia, hypernatremia, and mortality in patients with chronic kidney disease with and without congestive heart failure.

Pathophysiology of radiocontrast nephropathy: a role for medullary hypoxia.

Importance of venous congestion for worsening of renal function in advanced decompensated heart failure.

Long-term effects and prognosis in acute heart failure treated with tolvaptan: the AVCMA trial

Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.

Acute heart failure volume control multicenter randomized (AVCMA) trial: comparison of tolvaptan and carperitide

Clinical benefit of tolvaptan in patients with acute decompensated heart failure and chronic kidney disease.

P2888

s10157-016-1379-0

P304

858-865

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10157-016-1379-0

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Tetsuya Fujikawa

Nobuhito Hirawa

P577

2017-02-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28190113

http://www.w3.org/2001/XMLSchema#string

P932

5648735

http://www.w3.org/2001/XMLSchema#string

Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure.

about

P2860

P2860

Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P932